
Group 1 - Yili has launched three new infant formula products under the Jinlingguan brand in Hong Kong, marking its entry into the Hong Kong market and accelerating its global expansion strategy [1] - The infant formula and dairy products business, represented by Jinlingguan, has entered a steady expansion phase, achieving a revenue of 29.675 billion yuan, a year-on-year growth of 7.53%, with a gross margin of 41%, which is approximately 10 percentage points higher than the liquid milk business [1] - Jinlingguan's revenue has seen double-digit growth, with its retail market share increasing by two percentage points compared to the previous year [1] Group 2 - The declining birth rate in China presents challenges for the infant formula market, with expectations of further declines in the birth rate by 2025 [2] - Despite the challenges, there are structural opportunities in the market, and the infant formula industry is expected to enter a period of integration and structural adjustment by 2025 [2] - Yili will continue to focus on high-end positioning and innovation in its product offerings, responding to the increasing consumer demand for high-quality and scientifically formulated products [2] Group 3 - Yili has allocated a total subsidy of 1.6 billion yuan to provide at least 1,600 yuan in subsidies to eligible pregnant families across the country, including eight free nutritional products during pregnancy [3] - The subsidy program aims to support maternal and infant health, reflecting the company's commitment to social value and long-term brand investment [3] - The initiative is seen as a strategic investment in the future of maternal and infant health in China, benefiting many pregnant families in the short term while fostering a healthier environment for scientific parenting in the long term [3]